ArticleFrontiers in medicine2025
Spoligotyping-based molecular typing of
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the genetic makeup of Methods: A cross-sectional study was conducted among 390 suspected pulmonary TB patients. Sputum samples were examined using Ziehl-Neelsen staining and cultured, followed by molecular characterizations of the isolates using region of difference 9 (RD9) deletion typing and spoligotyping. Results: Out of 390 participants, 96 (24.6%) were smear positive, and 89 (22.8%) were culture positive. RD9 deletion typing confirmed 88 isolates as Conclusion: The high clustering rate observed may suggest recent transmission; however, this must be interpreted cautiously due to the limited discriminatory power of spoligotyping, which may overestimate clustering and underestimate diversity. This underscores the need for targeted TB control strategies informed by enhanced molecular surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.